Simvastatin-Tacrolimus and Simvastatin-cyclosporin interactions in rats

Biopharmaceutics and Drug Disposition

Volumn 19, Issue 5, 1998, Pages 279-284

  Yamada, Harumi ^a   Kotaki, Hajime ^a   Sawada, Yasufumi ^b   Iga, Tatsuji ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Creatine phosphokinase; Cyclosporin; Interaction; Rats; Simvastatin; Tacrolimus

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; CYCLOSPORIN A; SIMVASTATIN; TACROLIMUS;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CREATINE KINASE BLOOD LEVEL; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG EFFECT; DRUG METABOLISM; KIDNEY CLEARANCE; LIVER METABOLISM; MALE; NONHUMAN; RAT;

ANIMALS; CREATINE KINASE; CYCLOSPORINE; DRUG INTERACTIONS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LIVER; MALE; RATS; RATS, WISTAR; SIMVASTATIN; TACROLIMUS;

EID: 0031837091     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199807)19:5<279::AID-BDD101>3.0.CO;2-Q     Document Type: Article

References (41)

1. V.F. Mauro and J.L. MacDonald, Simvastatin: a review of its pharmacology and clinical use. D. I. C. P. Ann. Pharmacother., 25, 257-264 (1991).
2. P.A. Todd and K.L. Goa, Simvastatin: a review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs, 40, 583-607 (1990).
3. E.E. Slater and J.S. MacDonald, Mechanism of action and biological profile of HMG-CoA reductase inhibitors. Drugs, 36(Suppl. 3), 72-82 (1988).
4. S. Grimbert, D. Pessayre, C. Degott and J.P. Benhamou, Acute hepatitis induced by HMG-CoA reductase inhibitor, Lovastatin. Dig. Dis. Sci., 39, 2032-2033 (1994).
5. M.B. Jacobs, HMG-CoA reductase inhibitor therapy and peripheral neuropathy. Ann. Internal Med., 120, 970 (1994).
6. B.B. Schalke, B. Schmidt, K. Toyka and H.P. Hartung, Pravastatin-associated inflammatory myopathy. New Engl. J. Med., 327, 649-650 (1992).
7. N. Bizzaro, E. Bagolin, L. Milani, C. Cerser and B. Finco, Massive rhabdomyolysis and simvastatin. Clin. Chem., 38, 1504 (1992).
8. P. Chariot, R. Abadia, D. Agnus, C. Danan, C. Charpentier and R.K. Gherardi, Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am. J. Med., 94, 109 (1993).
9. H. Sylvain-Moor and J.P. Worden, Lovastatin-associated rhabdomyolysis. Heart Lung, 20, 464-466 (1991).
10. C.S. Wallace and B.A. Mueller, Lovastatin-induced rhabdomyolysis in the absence of concomitant drugs. Ann. Pharmacother., 26, 190-192 (1992).
11. J.A. Tobert, Lovastatin and myopathy. Am. J. Med., 96, 300-301 (1993).
12. M.A. Al-Jubouri, P.G. Briston, R.H. Chinn and R.M. Young, Myxoedema revealed by simvastatin induced myopathy. Br. Med. J., 308, 588 (1994).
13. K. Owen, C.R. Pick, S.E. Libretto and M.J. Adams, Toxicity of novel HMG-CoA reductase inhibitor in the common marmoset (Callithrix jacchus). Hum. Exp. Toxicol., 13, 357-368 (1994).
14. G.F. Zatara'n, V. Navarro, H. Garc'a and C. Calvo, Rhabdomyolysis and acute renal failure associated with lovastatin. Nephron, 66, 483-484 (1994).
15. D. Faulds, K.L. Goa and P. Benfield, Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs, 45, 953-1040 (1993).
16. M.J. Mihatsch, U. Helmuchen, P. Casanova, R. Habib, S. Larsen, A. Magil, L.H. Noel, J. Rapola, J. Ulrich and A.C. Wallace, Kidney biopsy findings in cyclosporin-treated patients with insulindependent diabetes mellitus. Klin. Wochenschr., 69, 354-359 (1991).
17. M.J. Mihatsch, G. Theil and B. Ryffel, Renal side-effects of cyclosporin A with special reference to auto immune diseases. Br. J. Dermatol., 122, 101-115 (1990).
18. Canadian-European Randomized Control Trial Group, Cyclosporininduced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes, 37, 1574-1582 (1988).
19. L.S. Ibels, J.H. Stewart, J.F. Mahony and A.G.R. Shell, Deaths from occlusive arterial disease in renal allograft recipients. Br. Med. J., 31, 552-554 (1974).
20. M.L. Nicholas and G.P.T. Alexandre, The evolution of hyperlipidemia late after renal transplantation. Proc. Eur. Dial. Transplant. Assoc., 16, 339-346 (1979).
21. R. Yoshimura, T. Oka, Y. Omori, T. Yasumura, I. Nakai, T. Hamasima, M. Okamoto, J. Yasui and T. Tanimura, The effect of pravastatin with hyperlipidemia. Jpn. J. Transplant., 26, 476-483 (1991).
22. P.F. Smith, R.S. Eydelloth, S.J. Grossman, R.J. Stubbs, M.S. Schwartz, J.I. Germershausen, K.P. Vyas, P.H. Kari and J.S. MacDonald, HMG-CoA reductase inhibitor-induced Myopathy in rat: Cyclosporin A interaction and mechanism studies. J. Pharmacol. Exp. Ther., 257, 1225-1235 (1991).
23. M.B. Regazzi, I. Iacona, C. Campana, V. Raddato, C. Lesi, G. Perani, A. Gavazzi and M. Vigano: Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant. Proc., 25, 2732-2734 (1993).
24. G. Blanson, J.C. Weber, D. Sachs, A.S. Korganow, T.G. Kretz and J.L. Pasquali, Rhabdomyolysis caused by simvastatin a patient following heart transplantation and cyclosporin therapy. Rev. Med. Intern., 13, 61-63 (1992).
25. P.E. Wallemacq and R. Reding, FK506(Tacrolimus), a novel immuno-suppressant in organ transplantation: clinical, biomedical, and analytical aspects. Clin. Chem., 39, 2219-2228 (1993).
26. M.A. Hooks, Tacrolimus, a new immunosuppressant - a review of the literature. Ann. Pharmacother., 28, 501-511 (1994).
27. I. Iacona, M.B. Regazzi, I. Buggia, P. Villani, V. Fiorito, M. Molinaro and E. Guarnone, High-performance liquid chromatography determination of pravastatin in plasma. Ther. Drug Monit., 16, 191-195 (1994).
28. T. Hashida, M. Ikenishi, Y. Toraguchi, Y. Tanigawara, M. Kimura, M. Yasuhara, R. Hori, K. Uemoto, Y. Tanaka and K. Ozawa, Therapeutic monitoring of tacrolimus using micro particle enzyme immunoassay method. TDM Kennkyuu, 11, 18-22 (1994).
29. FK506 kidney transplantation clinical trial group, Reliability of quantitative determination of FK506 in blood by IMx method using FK506-specific monoclonal antibody. Konnichi no ishyoku, 6, 227-230 (1993).
30. Y. Hayashi, N. Shibata, T. Minouchi, H. Shibata, T. Ono, H. Shimakawa, Evaluation of fluorescence polarization immunoassay for determination of cyclosporin in plasma. Ther. Drug Monit., 11, 205-209 (1989).
31. S. Hibi, A. Misawa, M. Tamai, K. Tsunamoto, S. Todo, T. Sawada, S. Imashuku, Severe rhabdomyolysis associated with tacrolimus. Lancet, 346, 702 (1995).
32. J.J. Fung, A. Todo, A. Jain, J. MacCauley, M. Alessiani, C. Scotti and T.E. Starzl, Conversion from cyclosporin to FK 506 in liver allograft recipients with cyclosporin-related complications. Transplant. Proc., 22, 6-12 (1990).
33. C.L. Corpier, R.H. Jones, W.N. Suki, E.D. Lederer, M.A. Quinones, S.W. Shmidt and J.B. Young, Rhabdomyolysis and renal injury with lovastatin use: Report of two cases in cardiac transplant recipients. J. Am. Med. Assoc., 260, 239-241 (1988).
34. M. Arnadottir, L.O. Erikeson, H. Thysell and J.D. Karkas, Plasma concentration profiles of simvastatin 3-hydroxy-3methylglutaril-Coenzyme A reductase inhibitory activity in kidney transplant recipients with and without cyclosporin. Nephron, 65, 410-413 (1993).
35. S. Vichers, C.A. Duncan, I.W. Chen, A, Rosegay and D.E. Duggan, Metabolic disposition studies on simvastatin, a cholesterol lowering prodrug. Drug Metab. Dispos., 18, 138-145 (1989).
36. R.W. Wang, P.H. Kari, A.Y.H. Lu and P.E. Thomas, Biotransformation of lovastatin: IV. Identification of cytocrome P450 3A protein as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch. Biochem. Biophys., 290, 355-361 (1991).
37. U. Christians, H.J. Schlitt, J.S. Bleck, H.M. Schiebel, R. Kownatzki, G. Maurer, S.S. Strohmeyer, R. Schottmann, K. Wonigeit and R. Pichlmayer, Measurement of cyclosporin and 18 metabolises in blood, bile and urine by high-performance liquid chromatography. Transplant. Proc., 20, 609-613 (1988).
38. M.R. Lucey, J.C. Kolars, R.M. Merion, D.A. Campbell, M. Aldrich and P.B. Watkins, Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA. Lancet, 355, 11-15 (1990).
39. T. Shiraga, H. Matsuda, K. Nagase, K. Iwasaki, K. Noda, H. Yamazaki, T. Shimada and Y. Funae, Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver. Biochem. Pharmacol., 47, 727-735 (1994).
40. T.N. Prasad, D.D. Stiff, N. Subbotina, M.A. Zemaitis, G.J. Burckart, T.E. Starzl and R. Venkataramanan, FK506 (Tacrolimus) metabolism by rat liver microsomes and its inhibition by other drugs. Res. Commun. Chem. Pathol. Pharmacol., 84, 35-46 (1994).
41. R. Assan, G. Fredj, E. Larger, G. Feutren and H. Bismuth, FK506/fluconazole interaction enhances FK506 nephrotoxicity. Diabet. Metab., 20, 49 (1994).